NCT02560389View on ClinicalTrials.gov

Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 1, 2018

Study Completion Date

May 1, 2018

Conditions
Stress Disorder, Post Traumatic
Interventions
DRUG

Placebo

Sugar pill packaged to resemble levodopa

DRUG

Levodopa

EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT02560389 - Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) | Biotech Hunter | Biotech Hunter